Date: 2012-03-08
Type of information: Results
phase: 2
Announcement: results
Company: Circassia (UK)
Product: ToleroMune® ragweed allergy vaccine
Action mechanism:
Disease: ragweed allergy
Therapeutic area: Allergic diseases - Immune diseases
Country: Canada
Trial
details: Circassia's latest phase II study was designed to assess the T-cell vaccine's efficacy and tolerability and to identify the optimal treatment regime. The trial was conducted in Canada in 275 ragweed allergy patients. During the randomised, double-blind, placebo-controlled trial, volunteers received one of four regimens of ToleroMune treatment over a three-month period. Patients were exposed to ragweed allergens in a validated exposure chamber, and investigators compared their nasal and ocular symptoms against the pre-treatment baseline.
Latest
news: Circassia Ltd, a specialty biopharmaceutical company focused on allergy, has announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial. The results show that the T-cell vaccine\'s optimal regimen substantially reduced patients' symptoms, achieving a 97% greater reduction than placebo (p?0.05) in subjects who had a moderate level of symptoms at baseline. The treatment was safe and well tolerated in all groups. The results were presented at the 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
